RS Oncology
Phase 2RS Oncology is a clinical-stage biotech developing novel PRX3-targeting therapies (such as RSO‑021) to fight oxidative-stress-dependent cancers like mesothelioma and metastatic disease.
Founded
2018
Focus
Small Molecules
About
RS Oncology is a clinical-stage biotech developing novel PRX3-targeting therapies (such as RSO‑021) to fight oxidative-stress-dependent cancers like mesothelioma and metastatic disease.
Company Info
TypePrivate
Founded2018
LocationCambridge, United States
StagePhase 2
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile